Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - drospirenone 3 mg (light yellow tablet); ethinylestradiol 0,02 mg (light yellow tablet); placebo (green tablet) - tablet - 3 mg - 0,02 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg (micro 15); ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) - tablet - 3mg/0.02mg - active: drospirenone 3mg (micro 15) ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) excipient: lactose monohydrate magnesium stearate maize starch opadry pink 02a34744 hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide hypromellose lactose monohydrate magnesium stearate maize starch povidone purified talc titanium dioxide - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ethinylestradiol, quantity: 0.02 mg; drospirenone, quantity: 3 mg - tablet - excipient ingredients: polacrilin potassium; magnesium stearate; lactose monohydrate - drospirenone/ethinyloestradiol-alphapharm 3/20 is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg/ethinyloestradiol 20 ?g tablets for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg/ethinyloestradiol 20 ?g tablets has not been evaluated for treatment of pms (premenstrual syndrome) (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Ireland - English - HPRA (Health Products Regulatory Authority)

gedeon richter plc - drospirenone; ethinylestradiol - film-coated tablet - 0.02 mg/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

gedeon richter plc - drospirenone; ethinylestradiol - film-coated tablet - 0.02 mg/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - drospirenone; ethinylestradiol - oral tablet - 3mg ; 20microgram

Canada - English - Health Canada

glenmark pharmaceuticals canada inc. - drospirenone; ethinyl estradiol - tablet - 3mg; 0.03mg - drospirenone 3mg; ethinyl estradiol 0.03mg - contraceptives